(Q51438639)

5 April 2018

title

Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. (English)

1 reference

5 April 2018

1 reference

1 reference

1 reference

Kinirons MT

1

1 reference

5 April 2018

O'Shea D

2

1 reference

5 April 2018

Kim RB

3

1 reference

5 April 2018

Groopman JD

4

1 reference

5 April 2018

Thummel KE

5

1 reference

5 April 2018

Wood AJ

6

1 reference

5 April 2018

Wilkinson GR

7

1 reference

5 April 2018

language of work or name

English

0 references

publication date

1 September 1999

1 reference

5 April 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

5 April 2018

volume

66

1 reference

5 April 2018

page(s)

224-231

1 reference

5 April 2018

issue

3

1 reference

5 April 2018

Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

In vitro and in vivo drug interactions involving human CYP3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Genetic polymorphism of S-mephenytoin hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Intersubject and dose-related variability after intravenous administration of erythromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Effect of age and gender on the activity of human hepatic CYP3A

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

First-pass metabolism of midazolam by the human intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Midazolam. A review of its pharmacological properties and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

The erythromycin breath test predicts the clearance of midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Cooperativity in oxidations catalyzed by cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Biliary excretion of erythromycin after parenteral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Assessment of urinary 6 beta-hydroxycortisol as an in vivo index of mixed-function oxygenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Expression of cytochrome P450 3A in amphibian, rat, and human kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Noninvasive tests of CYP3A enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970029-9

10.1016/S0009-9236(99)70029-9

7 January 2021

Identifiers

DOI

1 reference

5 April 2018

PubMed ID

10511057

1 reference

5 April 2018